Ligand Pharmaceuticals (LGND) Depreciation & Amortization (CF) (2010 - 2026)

Ligand Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $8.2 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $8.2 million, down 6.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.2 million (down 5.74% YoY), and the FY2025 annual result was $33.8 million, down 4.15% from the prior year.
• Depreciation & Amortization (CF) came in at $8.2 million for Q1 2026 at Ligand Pharmaceuticals, roughly flat from $8.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.7 million in Q1 2022 to a low of $8.2 million in Q4 2025.
• The 5-year median for Depreciation & Amortization (CF) is $8.9 million (2024), against an average of $9.7 million.
• Across the five-year window, Depreciation & Amortization (CF) gained 8.67% in 2022 and plunged 36.11% in 2023, its largest moves.
• Ligand Pharmaceuticals' Depreciation & Amortization (CF) stood at $11.1 million in 2022, then retreated by 19.93% to $8.9 million in 2023, then fell by 3.24% to $8.6 million in 2024, then decreased by 4.79% to $8.2 million in 2025, then gained by 0.02% to $8.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8.2 million (Q1 2026), $8.2 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.